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The Distribution of Congenital Anomalies Within the
VACTERL Association Among Tumor Necrosis Factor
Antagonist-exposed Pregnancies Is Similar to the
General Population
HUBERTINA J.M.J. CRIJNS, JANNEKE JENTINK, ESTER GARNE, CHRISTINE C. GISPEN-de WIED, 
SABINE M.J.M. STRAUS, LOLKJE T.W. de JONG-van den BERG, for the EUROCAT Working Group*
ABSTRACT. Objective. To compare the distribution of congenital anomalies within the VACTERL association (ver-
tebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients
exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population.
Methods.Analysis for comparison of proportional differences to a previous publication between anom-
aly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies
(EUROCAT), a population-based database.
Results. Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2
records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the catego-
ry “limb abnormalities” showed a significantly higher proportion in the general population.
Conclusion. The high number of congenital anomalies belonging to the VACTERL association from a
report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based
congenital anomaly database. (First Release July 1 2011; J Rheumatol 2011;38:1871–4; doi:10.3899/
jrheum.101316)
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Tumor necrosis factor-α (TNF-α) antagonists are indicated
for treatment of autoimmune disorders, which have a higher
incidence in women1. The teratogenic effect of TNF-α anta -
gonists is unknown.
A case of VACTERL association (vertebral defects, anal
atresia, cardiac, tracheoesophageal, renal, and limb abnormal-
ities; Table 1) due to in-utero exposure to a TNF-α antagonist
was identified by Carter, et al2. Based on this case, the US
Food and Drug Administration (FDA) Adverse Event
Reporting System (AERS) database was searched for confir-
mation of this association of in-utero exposure to TNF-α
antagonists3. Carter, et al concluded that their data suggest a
possible causative effect of in-utero exposure to TNF-α anta -
gonists and the VACTERL association.
A VACTERL association4 is defined by at least 3 of the
included congenital anomalies (Table 1) and is estimated to
occur in 1.6–2.9/10,000 live births5,6. Carter, et al3 also inves-
tigated the individual anomalies comprising the VACTERL
association instead of the defined presence of at least 3
 anomalies.
The FDA AERS database7 is designed to identify signals of
spontaneous reported adverse events in general, in contrast to
the European Surveillance of Congenital Anomalies (EURO-
CAT), a population-based database specifically designed to
identify and test signals of congenital anomalies7.
To assess whether in-utero exposure to TNF-α antagonists
would provide a higher risk of one or more of the anomalies
included in the VACTERL association, compared to the gen-
eral population, we compared the distribution of congenital
anomalies among the cases exposed to TNF-α antagonists as
presented by Carter, et al3 with the distribution of these anom-
alies in the EUROCAT database.
MATERIALS AND METHODS
The EUROCAT central database, covering a large European population, con-
tains individual standardized anonymous records of congenital anomalies
since 1980 including live births, stillbirths, or fetal death from 20 weeks of
gestational age, and terminations of pregnancy following prenatal diagnosis
of congenital anomalies of any gestational age8. The EUROCAT antiepileptic
study database is a validated part of the EUROCAT central database and can
be regarded as representative with respect to the distribution of congenital
anomalies in the general population based on several publications. For this
reason this dataset was used. This dataset comprises 98,075 major congenital
anomalies covering 3.8 million births. Medication use in this database is rep-
resentative for the use of medication in pregnancy in the general population
delivering a pregnancy outcome with congenital anomalies. We expect a low
prevalence of use of TNF-α antagonists in pregnancy (less than 1/1000). The
use of antiepileptic drugs noted in this database was 5.7/1000. That is very
low and therefore it is expected that there is no influence on the general dis-
tribution of specific birth defects9.
We classified the anomalies listed in Table 1 of the Carter publication3
according to EUROCAT anomaly subgroups. Only 31 of the 41 described
cases could be classified to the EUROCAT classification. Ten cases were
excluded because they contained unspecified congenital anomalies and minor
anomalies according to the EUROCAT classification and/or were infants and
fetuses with a chromosomal anomaly or single gene disorder (n = 3).
A working definition for VACTERL association was set up, as there are
several definitions for VACTERL association4. For correct comparison we
used the method used by Carter, et al3 (one or more congenital anomalies that
are part of VACTERL) as well as the agreed definition of at least 3 of the indi-
vidual anomalies present4, as listed in Table 1.
Analysis was performed comparing the proportion of different anomaly
subgroups as published by Carter, et al with proportions found in the EURO-
CAT database9, using the chi-square test to determine significance (p < 0.05).
RESULTS
The EUROCAT database contained 110 cases coded as VAC-
TERL association, which might be an underestimation. Using
the agreed VACTERL definition4, including at least 3 anom-
alies present, in the EUROCAT database, 619 (531 + 73 + 15,
respectively) cases fulfilled these criteria (Table 2).
Counting all individual anomalies in the VACTERL asso-
ciation solely, according to Carter’s definition, in the EURO-
CAT dataset, more than 50% of all cases of congenital anom-
aly would have a VACTERL association.
The congenital anomalies identified by Carter, et al includ-
ed 9 minor anomalies that are excluded in the EUROCAT
classification of malformations. These excluded anomalies
belonged to the EUROCAT subgroups eye, genital, muscu-
loskeletal, congenital heart disease, and respiratory.
Most cases from the Carter study had only one or 2 major
anomalies, so comparison of proportions is imprecise (Table
3). In this context, one significant observation was seen for
limb anomalies (p < 0.05).
DISCUSSION
This study shows that the cases with congenital anomalies
exposed to TNF-α antagonists as reported by Carter, et al
have a distribution of specific congenital anomalies similar to
those in a representation of the general population-based con-
genital anomaly database EUROCAT.
Based on currently known in-utero exposures to TNF-α
antagonists, no specific embryopathy has been identified10,11,12.
A limitation for comparison of results between the Carter
study and the EUROCAT data is the lack specificity of the
congenital anomalies by Carter, et al, and because of this sev-
eral anomalies could not be reclassified in detail according to
the EUROCAT anomaly subgroups. Because cases with only
minor anomalies are not included in the EUROCAT database,
these cases in the publication of Carter, et al were excluded in
our analysis.
Another possible limitation of our study is the difference
between the FDA database and our database. The FDA AERS
database is a spontaneous adverse reactions system and the
EUROCAT database is a population-based congenital anom-
aly database.
In studies on VACTERL associations, a definition of the
association should be included; for instance, the classic
VATER association described by Quan, et al13 does not
include the cardiac and limb associations described by Carter,
et al. Källén, et al4 verified the original VATER association
but not the extensions such as VACTERL.
Concluding protection by TNF-α antagonists for the con-
genital anomaly limb would be premature, because of the low
number of cases (n = 2) in the population described by Carter,
et al.
Our study was not designed to assess whether there is a
generalized increased risk of congenital anomalies with use of
TNF-α antagonists. In a postmarketing setting, 2 main
approaches have been used to identify teratogenic effects of
medicines, followup studies and case-control surveillance14.
Carter, et al suggested a large followup study of pregnancies
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Table 1. Congenital anomalies of the VACTERL association.
V Vertebral defects
A Anal atresia or imperforate anus
C Cardiac abnormalities, most commonly atrial septal defect, 
ventricular septal defect, and tetralogy of Fallot
T Tracheoesophageal fistula or tracheal atresia/stenosis
E Esophageal atresia
R Renal and/or radial abnormalities
L Pre-axial limb abnormalities
Table 2. Records of congenital anomalies included in the VACTERL
 definition in the EUROCAT database.
No. Congenital No. Records Proportion No. Cases
Anomalies Included in  in EUROCAT per 1000 Reported by 
the VACTERL Definition Antiepileptic Carter, et al3
Study Database
0 40498 413 17
1 53896 550 14
2 3061 31 8
3 531* 5 1
4 73* 1 0
5 15* 0 0
6 0 0 0
7 0 0 1**
* 619 (531 + 73 + 15) per 3.8 million = 1.6 per 10,000; see also Barnes and
Smith5. ** Proband case.
exposed to TNF-α antagonists, especially etanercept, to fur-
ther assess a possible increase in congenital anomalies.
Indeed, for this purpose, large pregnancy registries can be use-
ful; however, a case-control study might be more appropriate
to identify such a very rare association14.
The seemingly high number of congenital anomalies
belonging to the VACTERL spectrum within pregnancies
exposed to TNF-α antagonists described by Carter, et al could
not be confirmed. This neither reinforces nor excludes the
possibility of an increased absolute risk associated with
TNF-α antagonists. Evaluation of risks of specific major con-
genital malformations associated with use of TNF-α antago-
nists can be performed best in a case-control study database
designed to test signals of congenital anomalies14.
APPENDIX
List of study collaborators. Members of the European Surveillance of
Congenital Anomalies Working Group: C. Verellen-Dumoulin (Centre de
Génétique Humaine Institut de Pathologie et de Génétique), V. Nelen
(Provinciaal Instituut voor Hygiene), Belgium; I. Barisic (Children’s
University Hospital Zagreb), Croatia; B. Khoshnood (Institut National de la
Santé et de la Recherche Medicale), B. Doray (Registre des Malformations
Congenitales d’Alsace), France; S. Poetzsch (Otto-von-Guericke Universität
Magdeburg), A. Wiesel (Johannes Gutenberg Universität, Geburtenregister
Mainzer Modell), Germany; M. O’Mahony (Health Service Executive),
Ireland; A. Pierini (Istituto di Fisiologia Clinica del Consiglio Nazionale delle
Ricerche), F. Rivieri (Azienda Ospedaliero Universitaria di Ferrara), Italy; M.
Gatt (Department of Health Information and Research), Malta; M. Bakker
(University Medical Center Groningen, University of Groningen), The
Netherlands; K. Melve (Norwegian Institute of Public Health, Medical Birth
Registry of Norway), Norway; A. Latos-Bielenska, J.P. Mejnartowicz
(Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu), Poland;
I. Portillo (Direccion Salud Publica, Departamento Sanidad, Gobierno
Vasco), Spain; M-C. Addor (Registre Vaudois des Malformations),
Switzerland; D. Tucker (Swansea National Health Service Trust, Congenital
Anomaly Register and Information Service for Wales), D. Wellesley
(Southampton University Hospitals Trust), United Kingdom.
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